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Abstract
Bortezomib is a mainstay of therapy for multiple myeloma, frequently complicated by painful neuropathy. The objective of
this study was to describe clinical, electrophysiological, and pathological changes of bortezomib-induced peripheral neurop-
athy (BiPN) in detail and to correlate pathological changes with pain descriptors. Clinical data, nerve conduction studies, and
lower leg skin biopsies were collected from 22 BiPN patients. Skin sections were immunostained using anti-protein gene
product 9.5 (PGP9.5) and calcitonin gene-related peptide (CGRP) antibodies. Cumulative bortezomib dose and clinical
assessment scales indicated light-moderate sensory neuropathy. Pain intensity >4 (numerical rating scale) was present in
77% of the patients. Median pain intensity and overall McGill Pain Questionnaire (MPQ) sum scores indicated moderate to
severe neuropathic pain. Sural nerve sensory nerve action potentials were abnormal in 86%, while intraepidermal nerve fiber
densities of PGP9.5 and CGRP were not significantly different from healthy controls. However, subepidermal nerve fiber
density (SENFD) of PGP9.5 was significantly decreased and the axonal swelling ratio, a predictor of neuropathy, and upper
dermis nerve fiber density (UDNFD) of PGP9.5, presumably representing sprouting of parasympathetic fibers, were signif-
icantly increased in BiPN patients. Finally, significant correlations between UDNFD of PGP9.5 versus the evaluative
Pain Rating Index (PRI) and number of words count (NWC) of the MPQ, and significant inverse correlations between
SENFD/UDNFD of CGRP versus the sensory-discriminative MPQ PRI/NWC were found. BiPN is a sensory neuropathy, in
which neuropathic pain is the most striking clinical finding. Bortezomib-induced neuropathic pain may be driven by sprouting
of parasympathetic fibers in the upper dermis and impaired regeneration of CGRP fibers in the subepidermal layer.
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Introduction
Chemotherapy-induced peripheral neuropathy (CiPN) is
a disabling complication, occurring in 10%–50% of
patients who are treated for hematological malignan-
cies.1,2 Multiple myeloma (MM) is the most common
hematological malignancy, with an incidence of
4/100,000/year.3 Although an incurable disease, the life
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expectancy of MM patients has dramatically increased
with the advent of immunomodulatory drugs and pro-
teasome inhibitors about 10 years ago.4 Intravenous
(i.v.) bortezomib was the first proteasome inhibitor
used in clinical practice, firstly in refractory and relapsed
MM5–7 and later as first-line therapy.8,9 Since then,
different routes of administration and other proteasome
inhibitors have been used in clinical trials, such as
subcutaneous (s.c.) bortezomib,10 i.v. carfilzomib,11,12
and oral ixazomib,13 often with fewer and/or less
severe side effects. However, i.v. bortezomib alone or
in combination with other treatment modalities still is
a mainstay of therapy for MM.14,15
Bortezomib-induced peripheral neuropathy (BiPN)
may occur in up to 50% of patients treated with i.v.
bortezomib.16–18 The pathological mechanism of BiPN
has not been fully elucidated but involves both host, that
is, genetic factors,19–21 and dose-dependent direct toxic-
ity. Functional and pathological changes in animal
models of BiPN are most pronounced in unmyelinated
peripheral sensory axons22,23 and to a lesser extent pre-
sent in dorsal roots, dorsal root ganglion cells,24,25 and
satellite cells.22 It is hypothesized that these changes are
mediated through a toxic effect on mitochondria.23,26
Clinically, BiPN usually presents as a sensory, often
painful, length-dependent (i.e., the longest axons are
the earliest and the most affected) axonal peripheral
neuropathy,8,18,27–29 sometimes with autonomic nerve
fiber involvement.1,29 Rarely, a demyelinating neuropa-
thy with motor nerve involvement has been
described.28,30 BiPN, such as most CiPNs, usually has
a good prognosis, although some patients develop
life-long neuropathic pain or a debilitating sensory
neuropathy resulting in ataxia and reduced dexteri-
ty.1,17,18,29 Because currently there are no evidence-
based therapies for the prevention or treatment of
BiPN,31–33 early recognition is of utmost importance to
prevent irreversible neurological damage.1
Our first aim was therefore to describe the demo-
graphic, clinical, electrophysiological, and pathological
characteristics of BiPN in detail to aid in the diagnosis of
this disabling complication. Pathological changes in
nerve fibers were studied in skin biopsies from the
lower leg.34,35 Since we have previously hypothesized
that neuropathic pain may be driven by selective degen-
eration of subsets of unmyelinated nerve fibers in an
animal model of nerve-injury induced pain,36 the
second aim of the current study was to use BiPN as a
model for nerve-injury induced pain and to study corre-
lations between pathological changes in subsets of
unmyelinated nerve fibers in skin biopsies and neuro-
pathic pain descriptors. This way, we aim to test whether
the abovementioned hypothesis can be corroborated in
humans with neuropathic pain. Thus, BiPN may shed
light on mechanisms of neuropathic pain.
Patients and methods
Patients, clinical analyses, nerve conduction studies,
and skin biopsies
Between November 2008 and February 2012, 25 patients
with a suspected diagnosis of BiPN were referred to the
outpatient clinic of the Department of Neurology of
Erasmus MC, Rotterdam, the Netherlands. All patients
were treated with either bortezomib monotherapy or
bortezomib in combination with non-neurotoxic
chemo/immunotherapy, that is, hydroxydaunorubicin
(n¼ 8),9 lenalidomide (n¼ 2),37 or rituximab (n¼ 2).
After a diagnosis of BiPN was confirmed on clinical
grounds (i.e., a new diagnosis of peripheral neuropathy
or a clear deterioration of previously minimally symp-
tomatic peripheral neuropathy following bortezomib),
fulfilling the recently published ACTTION-APS Pain
Taxonomy diagnostic criteria for CiPN38 and the
Neuropathic Pain Special Interest Group guidelines for
neuropathic pain,39 22 patients and 17 healthy volun-
teers who served as controls for the skin biopsy measure-
ments (see subsection “Quantification of nerve fiber
densities and swellings”) consented in taking part in
the current study. Three patients were excluded because
there was no clear temporal relation between bortezomib
and the development of neuropathy. The study consisted
of the collection of demographic data and clinical data,
including pain intensity on a numerical rating scale
(NRS) and a sensory sum score that was specifically
designed and validated in our hospital to assess
CiPN.40 The sensory sum score is a compound measure
ranging from 0 to 11 of the presence (1) or absence (0) of
paresthesias, numbness, loss of dexterity, unsteadiness of
gait, normal (0) or abnormal (1) position sense, vibration
sense, pin-prick sensation, Romberg’s sign, Romberg’s
sign with heel-to-toe stand, knee reflex, and ankle reflex.
In addition, National Cancer Institute Common
Toxicity Criteria of Adverse Events (NCI-CTCAE)
v.3.0 for motor neuropathy, sensory neuropathy, and
neuralgia/pain (https://ctep.cancer.gov/protocoldevelop
ment/electronic_applications/docs/ctcaev3.pdf); McGill
Pain Questionnaires (MPQ; Dutch (n¼ 21) or English
(n¼ 1) language versions)41,42; nerve conduction studies
(NCS); and 3 mm skin biopsies at the right ankle were
performed/collected. For the MPQ, the sum of the
sensory-discriminative, affective, and evaluative Pain
Rating Indices (PRIs), and the overall sum of PRIs
were calculated.41,42 In addition, the sum of the
number of words count (NWC) for these items were
used.41,42 NCS consisted of sensory nerve conduction
of the sural, ulnar, and median nerve and motor nerve
conduction of the peroneal and median nerve. NCS was
conducted according to internationally accepted stand-
ards,43 and the 3% lower limit of normal of local
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reference values were used for statistical testing and to
determine the percentage of abnormal measurements.
The study was approved by the medical ethical commit-
tee of Erasmus MC (MEC-2008–305/NL24284.078.08)
and registered at clinicaltrials.gov (NCT00956033).
Histologic processing and immunohistochemistry of
skin biopsies
Skin biopsies were taken 10 cm above the right lateral
malleolus, under aseptic conditions, and using local
anesthesia with 1% lidocaine, using a 3-mm disposable
punch. The biopsies were immediately transferred to 2%
paraformaldehyde-lysine-sodium metaperiodate fixative
and fixed, processed, and stored at 80C according to
published guidelines.34 Before cutting, skin biopsies were
embedded in 12% gelatin, 10% sucrose blocks, which
were left in 4% paraformaldehyde for 2.5 h at room
temperature to harden. The gelatin blocks were then
kept overnight at 4C in a 30% sucrose solution.
Consequently, 50-lm sections were cut perpendicular
to the surface on a freezing microtome and processed
as free-floating sections.
The detailed immunohistochemical procedure is
described in a recent publication.36 In short, a two-step
immunohistochemistry with Streptavidin-Biotin Complex
was used for protein gene product 9.5 (PGP9.5), while
additional tyramid signal amplification was applied for
calcitonin gene-related peptide (CGRP). Concentrations
of primary antibodies were 1:10,000 for rabbit anti-PGP
9.5 (Catalog# ADI-905–520; Enzo Life Sciences,
Farmingdale, NY), 1:50,000 for guinea pig anti-CGRP
(Catalog # 16013; Progen Biotechnik, Heidelberg, DE),
and 1:100,000 for rabbit anti-CGRP (Catalog# PC205L;
Millipore, Billerica, MA). Omission of the primary anti-
bodies and preabsorbtion of the primary antibodies with
a more than 25 molar excess of the PGP9.5 protein or
CGRP peptide the primary antibodies were raised against
were used as negative control experiments.
Since it was impossible to process all sections in one
ImmunoRun, sections from 22 BiPN patients, 8 and 9
healthy controls were processed separately, and
each primary antibody (anti-PGP9.5 and guinea pig
anti-CGRP) was processed separately, although an
exactly similar immunohistochemical procedure
was followed each time. Thus, six ImmunoRuns were
performed altogether.
We also attempted to visualize the nonpeptidergic
subclass of nociceptors in the skin,36 using a histochem-
ical staining method (i.e., acetylcholinesterase)44 and
various immunohistochemical markers (i.e., P2X3, IB4,
RET, GINIP),36,45–47 at varying concentrations and
using specific protocols but were unable to obtain repro-
ducible staining patterns allowing for quantification
of these fibers.
Quantification of nerve fiber densities and swellings
For quantification of nerve fiber densities and axonal
swellings, slides were scanned and digitized using a
Hamamatsu NanoZoomer 2.0-HT slide scanner
(Hamamatsu Photonics, Hamamatsu City, JP).
Sections were analyzed using Leica Aperio ImageScope
software (freely available at www.leicabiosystems.com/
pathology-imaging/aperio-epathology/integrate/image
scope/) at 40magnification. Four sections per slide and
six frames per section were sampled. Frames were select-
ed so that they comprised the entire epidermis, subder-
mal layer, and at least 50 mm of upper dermis. The
following parameters were manually counted/traced for
both PGP9.5 and CGRP, by a single, blinded observer
(MB), as previously described36:
1. Intraepidermal nerve fiber density (IENFD) of
PGP9.5 and GCRP: the number of crossings of the
dermal–epidermal junction per millimeter length of
the epidermal surface.34 The length of the epidermal
surface was automatically determined by the
ImageScope software after tracing.
2. Subepidermal nerve fiber density (SENFD) of
PGP9.5 and GCRP: the number of immunolabeled
profiles within the subepidermal layer per millimeter
length of epidermal surface.48 Branches were not
counted as separate profiles.
3. Upper dermis nerve fiber density (UDNFD) of
PGP9.5 and GCRP: the number of immunolabeled
profiles within the upper dermis per millimeter
length of epidermal surface.48,49 Branches were not
counted as separate profiles.
4. Swelling ratio: the number of axonal swellings of
PGP9.5 labeled fibers, with a diameter of at least
two to three times the diameter of the axon, divided
by the number of intraepidermal nerve fibers, per mil-
limeter length of epidermal surface.50,51
Normative values of IENFD, SENFD, and UDNFD
of PGP9.5 and CGRP and axonal swelling ratio were
generated from skin biopsies of 17 healthy controls
that were processed in our laboratory using exactly the
same immunohistochemical and quantification protocol
as used for the BiPN skin biopsies.52
As a surrogate for nonpeptidergic innervation, we
also calculated IENFD, SENFD, and UDNFD of
(PGP9.5 minus CGRP) fibers, since the population of
peptidergic and nonpeptidergic nerve fibers are mostly
complementary.36
Statistical analysis
Mean and standard deviation (mean SD) of normally
distributed continuous variables and median and range
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(median [range]) of non-normally distributed continuous
variables were calculated. The Mann–Whitney test and
the chi-square test were used to compare age and sex of
healthy volunteers and BiPN patients. One-sample t tests
were used to compare nerve conduction velocity results
with normative values generated in our laboratory
of Clinical Neurophysiology. Mann–Whitney tests
for IENFD, SENFD, and UDNFD were used to com-
pare epidermal innervation of PGP9.5, CGRP, and
(PGP9.5-CGRP) and to compare axonal swelling
ratios in healthy volunteers and BiPN patients.
Bonferroni correction was applied for comparing
PGP9.5, CGRP, and (PGP9.5-CGRP) between healthy
volunteers and BiPN patients. Mann–Whitney tests, chi-
square tests, and independent samples t tests were used
to compare demographic data, clinical characteristics,
values of NCS, and skin innervation measurements of
BiPN patients who had received previous neurotoxic
chemotherapy with those of BiPN patients who had
not as well as to compare BiPN patients with a duration
of neuropathy symptoms 3 months with those with a
duration of symptoms >3 months. Spearman’s rank cor-
relation coefficients between pathological changes in
subsets of unmyelinated nerve fibers in skin biopsies
and neuropathic pain descriptors with p values were
determined. The statistical analysis was performed
using IBM SPSS Statistics v.21.0.0.0 software (IBM
Corp., Armonk, NY). All statistical tests were two-
sided with a significance level of 0.05.
Results
Clinical, electrophysiological and pathological
characteristics of BiPN
Demographic data and clinical and physiological char-
acteristics of the 22 patients with BiPN are listed in
Table 1. Patients were predominantly middle-aged
men, reflecting the prevalence of MM, which was the
most common underlying disorder. Three patients were
diagnosed with other plasma cell dyscrasias, that is,
Waldenstrom’s disease or plasma cell leukemia and
one patient with mantle cell lymphoma. Although 45%
of patients had received previous neurotoxic chemother-
apy (i.e., vincristine, thalidomide, or a combination of
these), only one of the patients had a minimally symp-
tomatic preexisting neuropathy (due to above average
alcohol consumption), based on a retrospective review
of the medical records. This, however, did not seem to
influence our conclusions (see below). The median dura-
tion of symptoms until patients were included in the
study was two months. Although the duration of symp-
toms was quite variable ranging from 0.5 to 24 months,
findings in patients with a duration of symptoms
3 months were similar to patients with the duration
of symptoms >3 months (see below). The age and sex
of the 22 patients with BiPN were not statistically sig-
nificantly different from the 17 healthy volunteers
(respective median [range] ages: 63 [39–79] and 63 [27–
78] years; male:female ratio of 19:3 and 10:7; p¼ 0.305,
Mann–Whitney test; p¼ 0.051, chi-square test).
A mean cumulative bortezomib dose of 15 mg/m2, a
mean sensory sum score of 6.8, and a median NCI-
CTCAE of 2 for sensory neuropathy and/or pain in
our patients indicated light-moderate sensory neuropa-
thy. Pain intensity >4 was present in 77% of the
patients, indicating small nerve fiber involvement in the
majority of cases, although orthostatic hypotension was
present in only 38% of patients. A median pain intensity
of 7 [0–9] and a mean overall sum of MPQ PRIs of
19 11 indicated moderate neuropathic pain. In addi-
tion, 55% of patients were using adjuvant analgesics
(i.e., antidepressants or anticonvulsants), while 27%
were using opioids.
Table 1. Demographic data and clinical characteristics.
n (%)¼ 22
Mean SD
Median
[range]
Demographic data
Age (years) 63 [39–79]
Sex (male) 19 (86%)
Diagnosis (multiple myeloma) 18 (82%)
Previous neurotoxic therapy 10 (45%)
Previous neuropathy 1 (4.5%)
Duration of BiPN (months) 2 [0.5–23]
Cumulative bortezomib dose (mg/m2) 15 7.9
Neurologic examination
SSS (0–11) 6.8 3.2
Orthostatic hypotension 8 (36%)
NCI-CTCAE sensory neuropathy 2 [0–3]
NCI-CTCAE neuralgia/pain 2 [0–3]
Neuropathic pain
Pain intensity (>4) 17 (77%) 7 [0–9]
McGill pain questionnaire
PRI-Sensory (0–36 points) 11 [4–22]
PRI-Affective (0–15 points) 3 [0–8]
PRI-Evaluative (0–12 points) 6 [2–9]
PRI-Total (0–63 points) 20 [10–37]
NWC-Sensory (0–12 words) 7 [3–12]
NWC-Affective (0–5 words) 7 [(0–5]
NWC-Evaluative (0–8 words) 3 [2–3]
NWC-Total (0–20 words) 13 [7–20]
Pain medication
Adjuvant analgesics 12 (55%)
Opioids/MED 6 (27%) 7 [7–60]
n¼ 22; SD: standard deviation; BiPN: bortezomib-induced peripheral
neuropathy; SSS: sensory sum score; NCI-CTCAE: National Cancer
Institute-Common Toxicity Criteria for Adverse Events; PRI: Pain Rating
Index; NWC: number of words count; MED: morphine equivalent dose.
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In Table 2, the results of NCS are summarized. Only
the mean sural nerve sensory nerve action potential
(SNAP) amplitude was below the 3% lower limit of
normal (LLN; in 19/22 or 86% of patients), based on
normative values generated in our laboratory of Clinical
Neurophysiology (p< 0.001; one-sample t test).
In Figure 1, representative PGP9.5 and CGRP immu-
nohistochemical staining patterns in the epidermis, sub-
epidermal layer, and upper dermis are presented, from
patients with BiPN (Figure 1(a) and (c)) and from healthy
volunteers (Figure 1(b) and (d)). PGP9.5 and CGRP both
labeled bundles of fibers just below and running parallel
to the basement membrane, which were sometimes asso-
ciated with blood vessels. From these bundles, thin and
varicose fibers originated that ran almost perpendicular to
their origins, thus penetrating the basement membrane.
In the epidermis, PGP9.5 labeled fibers were more abun-
dant, generally longer, sometimes reaching almost up to
the stratum corneum, and had more branches per unit
than CGRP fibers. The density of PGP9.5 and CGRP
intraepidermal nerve fibers appeared similar in healthy
volunteers and BiPN patients, although the density of
PGP9.5 fibers appeared lower in the subepidermal layer
and higher in the upper dermis in BiPN patients com-
pared to healthy volunteers. Looking in close detail (see
insets in Figure 1), PGP9.5-positive intraepidermal nerve
fibers also showed axonal swellings, both small (2–3 times
the nerve diameter) and large (>5 times the nerve diam-
eter). These nerve swellings were more abundant in BiPN
patients than in healthy volunteers.
To control for nonspecific staining of primary anti-
bodies, the same immunohistochemical protocol was
used, except that the primary antibodies were omitted
or preabsorbed with the protein or peptide they were
raised against, which resulted in a complete abolishment
of specific signal for all antibodies used (Figure 2(a)–(d)).
Guinea pig anti-CGRP (see also Axelsson et al.53) and
rabbit anti-CGRP (see also Bechakra et al.36) gave sim-
ilar staining patterns in the skin sections, although
guinea pig anti-CGRP showed less background staining
in our hands (Figure 2(e) and (f)). Therefore, guinea-pig
anti-CGRP was used for quantitative analyses. The
specificity of anti-PGP9.5 and anti-CGRP antibodies
has also been extensively tested on rat skins in previous
experiments in our laboratory.36
In Figure 3, the results of IENFD (Figure 3(a)),
SENFD (Figure 3(c)), and UDNFD (Figure 3(d)) of
PGP9.5, CGRP, and (PGP9.5-CGRP) are summarized,
in healthy volunteers and BiPN patients. Swelling ratios
of intraepidermal PGP9.5 fibers are presented in
Figure 3(b). SENFD of PGP9.5 and (PGP9.5-CGRP)
was significantly decreased, while UDNFD of PGP9.5
and (PGP9.5-CGRP) and the axonal swelling ratio were
significantly increased in BiPN patients compared to
healthy volunteers (p< 0.001, p< 0.001, p< 0.001,
p¼ 0.001 and p¼ 0.001 respectively; Mann–Whitney
tests, using Bonferroni correction with an adjusted sig-
nificance of 0.017).
To control for a potential influence of previous neu-
rotoxic chemotherapy on clinical characteristics, values
of NCS and skin innervation measurements, BiPN
patients who had received previous neurotoxic chemo-
therapy (n¼ 10) were compared with BiPN patients who
had not (n¼ 12). None of the 41 outcome measures in
Tables 1 and 2 and Figure 3 were significantly different
(p> 0.05; uncorrected Mann–Whitney, chi-square tests
and independent-samples t tests), except that the
median age of former group (58 years) was lower than
that of the latter (65 years) (uncorrected p¼ 0.026;
Mann–Whitney test). The age-dependent outcome meas-
ures mean sural nerve amplitude was 1.4 mV (9/10
patients below the LLN) in the pretreated group and
1.7 mV (10/12 patients below the LLN) in the nonpre-
treated group, median IENFD of PGP9.5 was 5.5/mm in
the pretreated group and 5.1/mm in the nonpretreated
group (uncorrected p¼ 0.88 and 0.60, respectively;
independent-sample t test, Mann–Whitney test).
To control for a potential influence of the duration of
symptoms on clinical characteristics, values of NCS and
skin innervation measurements, patients with a duration
of symptoms 3 months (i.e., (sub)acute neuropathy;
n¼ 16) were compared with patients with a duration of
symptoms >3 months (i.e., chronic neuropathy; n¼ 6).
None of the 41 outcome measures in Tables 1 and 2
Table 2. Mean SD values of nerve conduction studies.
SNAP (mV) NCV (m/s) CMAP (mV)
Sural nerve 1.5 2.3*** (86%) 39.3 5.9a (50%) –
Ulnar nerve 6.2 7.4 (50%) 42.3 6.9a (60%) –
Median nerve 9.9 7.2 (43%) 43.5 7.9a (52%) 7.2 1.6 (0%)
Peroneal nerve – 39.3 6.8b (26%) 2.1 2.3 (50%)
Note: Percentages between brackets indicate the fraction of patients with abnormal values compared to normative values; one
sample t test; n¼ 22. CMAP: compound muscle action potential; SNAP: sensory nerve action potential; NCV: nerve con-
duction velocity; SD: standard deviation.
aSensory NCV; bMotor NCV.
***p< 0.001.
Bechakra et al. 5
and Figure 3 were significantly different (p> 0.05;
uncorrected Mann–Whitney, chi-square tests, and
independent-samples t tests).
Correlations between pathological changes in subsets
of unmyelinated nerve fibers in skin biopsies and
descriptors of BiPN-induced neuropathic pain
There were no statistically significant correlations
between cumulative bortezomib dose, SSS, NCI-
CTCAE, sural nerve SNAP, IENFD of PGP9.5, and
swelling ratio on the one hand, and NRS, MPQ overall
sum of PRIs, adjuvant analgesic medication, and mor-
phine equivalent dose on the other hand (p> 0.05;
Spearman’s correlations), except for correlations between
NCI-CTCAE sensory neuropathy and neuralgia/pain
versus adjuvant analgesic medication (uncorrected
p¼ 0.047 and 0.030; Spearman’s correlations).
In Table 3, correlations between the nerve fiber den-
sities for each immunohistochemical marker versus the
sensory-discriminative, affective, and evaluative MPQ
PRIs and NWCs are presented, with their respective
uncorrected p values. Here, correlations between
UDNFD of PGP9.5 versus the evaluative MPQ PRI
(q¼ 0.447) and NWC (q¼ 0.427) were found, and
inverse correlations between UDNFD of CGRP versus
the sensory-discriminative MPQ PRI (q¼0.422) and
SENFD of CGRP versus the sensory-discriminative
MPQ NWC (q¼0.423) were found (p  0.05;
Spearman’s correlations). In addition, p values 0.1
were demonstrated for inverse correlations between
IENFD and UDNFD of CGRP versus the sensory-
Figure 1. Immunohistochemical staining patterns of PGP9.5 (a and c) and CGRP (b and d) in BiPN patients (a and b) and healthy
volunteers (c and d). (e) to (h) represent high-power insets, which enable to visualize the length of the intraepidermal fibers, branching
pattern and intraepidermal axonal swellings. Red arrows represent intraepidermal nerve fibers, white arrows represent subepidermal
nerve fibers, black arrows represent upper dermal nerve fibers, and green arrows represent axonal swellings. The white bars measure
50mm. CGRP: calcitonin gene-related peptide; PGP9.5: protein gene product 9.5.
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discriminative MPQ PRI and NWC and positive
correlations between IENFD of PGP9.5 and
(PGP9.5-CGRP) versus the affective MPQ PRI
(0.422< q< 0.413; p  0.1; Spearman’s correlations,
for exact values of q and p, see Table 3).
Discussion
Our study reports the clinical, electrophysiological and
pathological changes in a cohort of 22 patients with
BiPN. The results indicate a light-moderate sensory neu-
ropathy, in which neuropathic pain is the most striking
clinical finding. NCS was within the normal range, apart
from a significantly reduced mean sural nerve SNAP
which was below the lower limit of normal in 86% of
patients, consistent with a length-dependent axonal sen-
sory neuropathy. IENFD of PGP9.5 was not significant-
ly decreased compared to healthy volunteers. SENFD of
PGP9.5, however, was significantly lower than in healthy
volunteers. Furthermore, the axonal swelling ratio and
UDNFD of PGP9.5 were significantly increased.
Finally, significant positive correlations between
UDNFD of PGP9.5 versus the evaluative PRI and
NWC of the MPQ, and significant inverse correlations
between SENFD of CGRP versus the sensory-
discriminative MPQ NWC and UDNFD of CGRP
versus the sensory-discriminative MPQ PRI were found.
Clinical, pathological and electrophysiological
characteristics of BiPN
All patients were treated with either bortezomib mono-
chemotherapy or bortezomib in combination with non-
neurotoxic chemo/immunotherapy. Although the fact
that 45% of the patients had received previous neuro-
toxic therapy is a potential weakness of this study, out-
come measures were not significantly different between
BiPN patients who had received previous neurotoxic
therapy and patients who had not, except that the
median age of the pretreated group was seven years
younger. There is no reason to suspect that this relatively
small age difference might (indirectly) have influenced
Figure 2. Immunohistochemical staining patterns of PGP9.5 (a) and CGRP (guinea-pig) (c) and using preabsorbtion controls (b and d), in
normal skins. Immunohistochemical staining patterns in normal skins, comparing a guinea pig (e) and a rabbit anti-CCRP antibody (f). The
white bar measures 50 mm.
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our conclusions, since the age-dependent outcome mea-
sure sural nerve amplitude was also abnormal in 10/12 of
nonpretreated patients and IENFD of PGP9.5 was (not
significantly) higher in the pretreated group. Thus, even
if baseline data were not systematically assessed, our
study population was quite homogeneous and there
were no major confounding factors. In addition, the
wide range of the duration of symptoms did not seem
to affect our conclusions.
In comparison to earlier reports of BiPN, the
cumulative bortezomib dose at the presentation of
neuropathy was relatively low and the severity
of neuropathy in our cohort was rather mild.8,9,18,54
An obvious reason may be the fact that the
referring hemato-oncologists in our academic cancer
center are very keen on a suspected evolving neurop-
athy and had sent those patients to our Outpatient
Clinic of Neurology for consultation at an early
Figure 3. Skin innervation measurements in BiPN patients (n¼ 22) and healthy volunteers (n¼ 17). Box plots showing the median,
interquartile range, range, and outliers of the number of intraepidermal (IENFD; a), subepidermal (SENFD; c), upper dermal (UDNFD; d)
nerve fiber density, and the axonal swelling ratios (b), using PGP9.5, CGRP, and (PGP9.5-CGRP) as markers to measure the total number of
fibers and peptidergic and nonpeptidergic subclasses, ***p  0.001; Mann–Whitney tests, using Bonferroni correction with an adjusted
significance level of 0.017.
Table 3. Correlations between immunohistochemical markers and MPQ, PRI, and NWC.
MPQ
IENFD SENFD UDNFD
PGP9.5 CGRP PGP-CGRP PGP9.5 CGRP PGP-CGRP PGP9.5 CGRP PGP-CGRP
PRI-Sensory 0.637 0.106 0.079 0.382 0.694 0.089 0.648 0.103 0.139 0.326 0.240 0.261 0.553 0.134 0.050 0.422* 0.596 0.120
PRI-Affective 0.056 0.413 0.825 0.050 0.075 0.388 0.466 0.164 0.903 0.028 0.206 0.280 0.576 0.126 0.831 0.048 0.533 0.140
PRI-Evaluative 0.271 0.245 0.276 0.243 0.388 0.193 0.192 0.289 0.618 0.113 0.943 0.016 0.037 0.447* 0.427 0.179 0.231 0.266
NWC-Sensory 0.998 0.001 0.064 0.401 0.939 0.017 0.405 0.187 0.050 0.423* 0.312 0.226 0.189 0.291 0.071 0.392 0.883 0.033
NWC-Affective 0.457 0.167 0.421 0.181 0.453 0.169 0.760 0.069 0.923 0.022 0.216 0.275 0.926 0.007 0.407 0.186 0.674 0.095
NWC-Evaluative 0.621 0.111 0.088 0.373 0.805 0.056 0.935 0.019 0.279 0.241 0.279 0.241 0.047 0.427* 0.870 0.037 0.107 0.353
Note: Numerals in the left column refer to p values, and numerals in the right column refer to Spearman’s correlation coefficients. Correlation coefficients
with an uncorrected p  0.05 are printed in bold with an asterisk, correlation coefficients with a p  0.1 are printed in italics; n¼ 22. MPQ: McGill Pain
Questionnaire; IENFD: intraepidermal nerve fiber density; SENFD: subepidermal nerve fiber density; UDNFD: upper dermis nerve fiber density; CGRP:
calcitonin gene-related peptide; PGP: protein gene product.
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stage. This has to be taken into consideration when
comparing our results with the literature.
Since it was previously suggested that predominantly
small diameter nerve fibers are affected in BiPN27,55
,17,18, skin biopsies were collected and analyzed for inner-
vation densities in all patients, as the epidermis exclu-
sively contains unmyelinated nerve fibers.56 Although an
immunofluorescent technique may give clearer labeling,
less background staining and provide an opportunity for
double and triple labeling,57,58 bright field immunohis-
tochemistry was used to label nerve fibers in this study,
since we have previously validated this technique and
reference values were generated in our own lab. Apart
from a few cases8,55,59 and a small cohort,60 systematic
skin biopsies in patients with BiPN have not been
reported. The aforementioned studies represent highly
selected cases or a small series as part of CiPN in gen-
eral; therefore, it is impossible to draw any conclusions
about the validity of IENFD in BiPN from them. Our
study is the first that systematically assesses nerve fiber
densities of PGP9.5 and CGRP in skin biopsies from
BiPN patients. Skin biopsies were obtained from the
hairy skin at the ankle and processed and quantified
according to published international guidelines.34,35 We
not only assessed IENFD of PGP9.5, but also SENFD
and UDNFD,48,49 since these measures may provide
additional information on innervation changes in the
skin, especially in relation to neuropathic pain indices.48
In addition, IENFD, SENFD and UDNFD were deter-
mined for CGRP.48 CGRP is generally considered
a valid marker for the peptidergic subclass of
C-fibers,36,61 which is localized within sympathetic
nerve fibers as well.62 Direct staining of the nonpeptider-
gic subclass of nerve fibers in the skin biopsies was
unsuccessful (see Materials and Methods section). As
far as we are aware there are no reports in the literature
regarding quantifiable (epi)dermal labeling of nonpepti-
dergic nerve fibers in humans either. Since it is hypoth-
esized that peptidergic and nonpeptidergic nociceptors
are mostly complementary and may each convey specific
information about pain along labeled lines to the spinal
cord and brain,63,64 we decided to use IENFD, SENFD
and UDNFD of the difference (PGP9.5-CGRP) as sur-
rogate markers for the number of nonpeptidergic fibers
in order to get a complete picture of skin innervation in
our cohort of BiPN patients. Finally, since our cohort
contained patients with relatively mild BiPN, we also
calculated the percentage of axonal swellings in epider-
mal PGP9.5 fibers, which may be considered an
early indicator of nerve degeneration, preceding nerve
terminal loss.50,51,65
Contrary to the notion that bortezomib predominant-
ly affects small diameter nerve fibers, we found that the
sural nerve SNAP, which only represents large diameter
nerve fibers, was significantly decreased, while IENFD
of PGP9.5 and CGRP were not. One explanation for
this lack of a decrease in IENFD may be the fact that
the main symptoms of BiPN are focused in the glabrous
skin under the foot while skin biopsies were collected
10 cm above the lateral malleolus (according to interna-
tional guidelines).34 Furthermore, NCS is a physiologi-
cal measure to evaluate functional pathology while
Wallerian degeneration, that is, structural damage,
may only occur at a later stage. A significant increase
in the axonal swelling ratio of unmyelinated epidermal
nerve fibers is in line with this idea. Secondly, SENFD of
PGP9.5 was decreased in our cohort of BiPN patients, as
has also been observed in other neuropathies with small
nerve fiber involvement.48,49 Our observations therefore
confirm that bortezomib does affect small diameter
nerve fibers indeed.
Correlations between pathological changes in subsets
of unmyelinated nerve fibers in skin biopsies and
descriptors of BiPN-induced neuropathic pain
Neuropathic pain was the most prevalent symptom in
our cohort of BiPN patients, occurring in 77% of
patients. No consistent correlation between changes in
(epi)dermal innervation and neuropathic pain intensity
has been described in patients with neuropathy.48,56,66
This may be caused by mixed pathology, for example,
in painful diabetic neuropathy, or by the fact that selec-
tive degeneration of a subset of nociceptors, which may
not be detected using the pan axonal marker PGP9.5,
may drive hyperalgesia and eventually neuropathic
pain.36 Our cohort of BiPN-patients was very well
suited to study the pathophysiological changes that
may lead to neuropathic pain, since there was no
mixed pathology and we used both CGRP immunohis-
tochemistry and a (surrogate) marker for nonpeptidergic
nerve fibers.
It has previously been demonstrated that sprouting of
parasympathetic fibers into the upper dermis occurs due
to the loss of nonpeptidergic fibers in the subepidermis,
while sprouting of sympathetic fibers into the
upper dermis occurs due to the loss of peptidergic
fibers.45,67,68 We found an increased UDNFD of
PGP9.5 and a decreased SENFD of (PGP9.5-CGRP),
while UDNFD of CGRP, which is also expressed in
sympathetic neurons,62 was not increased, and there
was no loss of peptidergic fibers in the subepidermis.
Therefore, even if we did not provide direct evidence,
we suggest that the increased UDNFD of PGP9.5 rep-
resents sprouting of parasympathetic fibers. Although
less studied than the sympathetic nervous system in
mediating chronic pain, acetylcholine from parasympa-
thetic nerve fibers may also sensitize nociceptor
terminals in the skin.69,70 Furthermore, the apparent
sprouting of parasympathetic fibers in the upper
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dermis appeared to correlate with the evaluative PRI
and NWC of the MPQ. Thus, our findings may indicate
that parasympathetic fiber sprouting into the upper
dermis plays a role in mediating neuropathic pain, spe-
cifically the evaluative component.
A second striking finding was that SENFD of CGRP
was not significantly reduced, although SENFD of
PGP9.5 and (PGP9.5-CGRP) were. This may suggest
that CGRP-fiber reinnervation of the subepidermis,
which has been shown previously in rats,36,71 also
occurs in humans. Apparently, this reinnervation was
insufficient to salvage normal pain sensation, since
SENFD of CGRP was negatively correlated with the
sensory-discriminatory NWC of the MPQ, and
UDNFD of CGRP was negatively correlated with the
sensory-discriminatory PRI. Borderline significant nega-
tive correlations of IENFD of CGRP and UDNFD of
CGRP versus sensory-discriminative PRI and NWC fur-
ther support this notion.
In contrast, a borderline significant positive correla-
tion of IENFD of PGP9.5 and (PGP9.5-CGRP) versus
the affective PRI of the MPQ was found, highlighting
the possibility that reinnervation of nonpeptidergic
nerve fibers directly or indirectly (i.e., via parasympa-
thetic sprouting, see above) contributes to the affective
component of BiPN-induced neuropathic pain. This
component may be further modulated at the spinal
level via glumate receptors.72,73
Taken together, the observed correlations of CGRP
nerve fibers with the sensory-discriminative component,
of parasympathetic nerve fibers with the evaluative com-
ponent and possibly nonpeptidergic nerve fibers with the
affective component of neuropathic pain fit well with the
hypothesis of parallel pain pathways that serve different
pain qualities.36,63,64 It also fits with the clinical obser-
vation that neuropathic pain patients often report rela-
tively mild pain intensities on a NRS scale (the sensory-
discriminative component) in relation to their suffering
(the evaluative and affective component), since nonpep-
tidergic afferents may be more characteristically
involved in neuropathic pain.72
In conclusion, BiPN is a sensory neuropathy, in
which neuropathic pain is the most striking clinical find-
ing. Since IENFD of PGP9.5 may be normal, NCS and
axonal swelling ratios may be more sensitive ancillary
investigations. Secondly, nociceptor subset specific
changes may (directly or indirectly) contribute to the
sensory-discriminative, evaluative, and affective compo-
nents of neuropathic pain. Although the MPQ is imprac-
tical for use in routine clinical practice, we suggest to
rate pain intensity as well as pain unpleasantness,
using a NRS, to take into account both the sensory-
discriminative and the and affective components of neu-
ropathic pain in BiPN patients. Furthermore, selective
targeting of these subsets may increase our
understanding of neuropathic pain and may aid in devel-
oping better pharmaceuticals that alleviate not only pain
intensity but also the affective component of neuropath-
ic pain.
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